

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of Optineurin E50K D474N E478A [1 - 577]

Enzyme description:- Optineurin E50K D474N E478A [1 – 577]

Clone number:- DU 4826

Source:- Recombinant

Expression system:- *E.coli*

Tag:- N-terminal GST

Purification method:- GSH Sepharose

Calculated molecular mass:-

Monoisotopic 92, 613.86 daltons

Average Mass 92, 672.22 daltons

[cysteines reduced, methionines have not been oxidised]

Theoretical pI:- 5.32

Purity:- >80 %

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM Sucrose, 150 mM NaCl, 0.1 mM EGTA,
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF

Storage temperature:- -70 °C

Division of Signal Transduction Therapy

Clone Data Sheet

Optineurin E50K D474N E478A [1 – 577]

| | |
|--------------------------------------|--|
| <u>Protein</u> | Optineurin E50K D474N E478A [1 – 577] |
| <u>Clone number</u> | DU 4826 |
| <u>Species</u> | Human |
| <u>Accession number</u> | AF420371 |
| <u>Tags</u> | N-terminal GST |
| <u>Bacterially expressed protein</u> | <p>MSPILGYWKIKGLVQPTRLLEYLEEKYEHLIERDEGDKWRNKKFELG LEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAIEISMLEGA VLDIRYGVSRIAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLNGDH VTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSS KYIAWPLQGWQATFGGGDHPKSDLEVLFGQPLGSMHQPLSCLTEKED SPSESTGNGPPHLAHPNLDFTTPEELLQOMKELLTKNHQLKEAMKLNNQ AMKGRFEELSAWTEKQKEERQFFEIQSKEAKERLMALSHENEKLKEELG KLKGKSERSSDPTDDSRLLPRAEAEQEKDQLRTQVVRLOAEKADLLGIV SELQKLNSSGSSSEDSFVEIRMAEGEAEGSVKEIKHSPGPTRTVSTGTA LSKYRSRSADGAKNYFEHEELTVSOLLCLREGNQKVERLEVALKEAKE RVSDFEKKTNRSEIETQTEGSTEKENDEEKGPETVGSEVEALNLQVTS LFKELQEAHTKLSEAELMKKRLQEKQALERKNSAIPSELNEKQELVYT NKKLELQVESMLSEIKMEQAKTEDEKSKLTVLQMTNKLLOEHNALKT IEELTRKESEKVDRAVLKELSEKLELAEKALASKQLQMDQEMKQTIKQ EDLETMTILRAQMEVYCSNFHAARAAREKIHEEKEQLALQLAVLLKEND AFEDGGRQSLMEMQSRHGARTSDSDQQAYLVQVQGAEDRDWRQQRNIPIH SCPCKGEVLPDIDTLQIHVMDCII</p> |
| <u>Native sequence</u> | <p>Amino acids M1 – I577 (end) of human Optineurin. Residue M232 of the fusion protein is equivalent to M1 of the native enzyme. The GST tag is located at residues 1 – 220. The protein has an E50K mutation, a D474N mutation and an E478A mutation. Residue E50 is equivalent to residue K281 of the fusion protein. Residue D474 is equivalent to residue N705 of the fusion protein. And residue E478 is equivalent to residue A709 of the fusion protein.</p> |
| <u>Protease cleavage</u> | PreScission (<u>LEVLFGQP</u>) residues 221 - 228 |
| <u>Cloning sites</u> | <i>Bam</i> H1 and <i>Not</i> 1 sites of pGEX6P-1 |

Division of Signal Transduction Therapy

Complete Nucleotide Sequence:

ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCAC
TCGACTTCTTTTGGAAATATCTTGAAGAAAAATATGAAGAGCATTGTATG
AGCGCGATGAAGGTGATAAATGGCGAAACAAAAAGTTTGAATTGGGTTTG
GAGTTTCCCAATCTTCTTATTATATTGATGGTGATGTTAAATTAACACA
GTCTATGGCCATCATACTTATATAGCTGACAAGCACACATGTTGGGTG
GTTGTCCAAAAGAGCGTGCAGAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTCGAGAATTGCATATAGTAAAGACTTTGAAAC
TCTCAAAGTTGATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTCG
AAGATCGTTTATGTCATAAAACATATTTAAATGGTGATCATGTAACCCAT
CCTGACTTCATGTTGTATGACGCTCTTGATGTTGTTTTATACATGGACCC
AATGTGCCTGGATGCGTTCCTAAAATTAGTTTGTTTTAAAAACGTATTG
AAGCTATCCCACAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCC
AAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCTGGGATCCATGTCCC
ATCAACCTCTCAGCTGCCTCACTGAAAAGGAGGACAGCCCCAGTGAAAGC
ACAGGAAATGGACCCCCCACCTGGCCACCCAAACCTGGACACGTTTAC
CCCGGAGGAGCTGCTGCAGCAGATGAAAGAGCTCCTGACCAAGAACCACC
AGCTGAAAGAAGCCATGAAGCTAAATAATCAAGCCATGAAAGGGAGATTT
GAGGAGCTTTCGGCCTGGACAGAGAAAACAGAAGGAAGAACGCCAGTTTTT
TGAGATACAGAGCAAAGAAGCAAAGAGCGTCTAATGGCCTTGAGTCATG
AGAATGAGAAATTGAAGGAAGAGCTTGGAAAACAAAAGGGAAATCAGAA
AGGTCATCTGAGGACCCCACTGATGACTCCAGGCTTCCCAGGGCCGAAGC
GGAGCAGGAAAAGGACCAGCTCAGGACCCAGGTGGTGAGGCTACAAGCAG
AGAAGGCAGACCTGTTGGGCATCGTGTCTGAACTGCAGCTCAAGCTGAAC
TCCAGCGGCTCCTCAGAAGATTCCTTTGTTGAAATTAGGATGGCTGAAGG
AGAAGCAGAAGGGTCAGTAAAAGAAATCAAGCATAGTCCTGGGCCACGA
GAACAGTCTCCACTGGCACGGCATTGTCTAAATATAGGAGCAGATCTGCA
GATGGGGCCAAGAATTACTTCGAACATGAGGAGTTAACTGTGAGCCAGCT
CCTGCTGTGCCTAAGGGAAGGGAATCAGAAGGTGGAGAGACTTGAAGTTG
CACTCAAGGAGGCCAAAAGAAAGAGTTTCAGATTTTGAAAAGAAAACAAGT
AATCGTCTTGAGATTGAAACCCAGACAGAGGGGAGCACAGAGAAAGAGAA
TGATGAAGAGAAAGGCCCGGAGACTGTTGGAAGCGAAGTGGAAGCACTGA
ACCTCCAGGTGACATCTCTGTTTAAGGAGCTTCAAGAGGCTCATACAAAA
CTCAGCGAAGCTGAGCTAATGAAGAAGAGACTTCAAGATAAGTGTGAGGC
CCTTGAAAGGAAAAATCTGCAATTCCATCAGAGTTGAATGAAAAGCAAG
AGCTTGTTTATACTAACAAAAAGTTAGAGCTACAAGTGGAAAGCATGCTA
TCAGAAATCAAATGGAACAGGCTAAAACAGAGGATGAAAAGTCCAAATT
AACTGTGCTACAGATGACACACAACAAGCTTCTTCAAGAACATAATAATG
CATTGAAAACAATTGAGGAACTAACAAAGAAAAGAGTCAGAAAAAGTGGAC
AGGGCAGTGCTGAAGGAACTGAGTGAAAAACTGGAAC TGGCAGAGAAGGC
TCTGGCTTCCAAACAGCTGCAAATGGATGAAATGAAGCAAACCATTGCCA
AGCAGGAAGAGGACCTGGAACCATGACCATCCTCAGGGCTCAGATGGAA
GTTTACTGTTCTAATTTTCATGCTGCAAGAGCAGCGAGAGAGAAAATTCA
TGAGGAAAAGGAGCAACTGGCATTGCAGCTGGCAGTTCTGCTGAAAGAGA
ATGATGCTTTCGAAGACGGAGGCAGGCAGTCCCTTGATGGAGATGCAGAGT

Division of Signal Transduction Therapy

CGTCATGGGGCGAGAACAAGTGACTCTGACCAGCAGGCTTACCTTGTTCA
AAGAGGAGCTGAGGACAGGGACTGGCGGCAACAGCGGAATATTCGGATTC
ATTCCTGCCCCAAGTGTGGAGAGGTTCTGCCTGACATAGACACGTTACAG
ATTCACGTGATGGATTGCATCATTtaagcggccgc